Latest Oncology News

August 04, 2021

Two years after being diagnosed with multiple myeloma and treated with the Dara-Rd regimen as induction therapy, a 78-year-old patient presented with mild fatigue during routine follow-up. James E. Hoffman, MD, discussed the case with a group of peers.

August 04, 2021

Research in the solid tumors arena around the combination of the oncolytic virus technology CF33-CD19 and the CD19-targeting CAR placental-derived T-cell therapy CyCART-19, is underway to explore it’s potential in this patient population.

August 04, 2021

Following the success of a phase 1 study that showed its potential for accelerated FDA approval in the future, the WEE-1 inhibitor, ZN-c3 has been dosed for the first time in the newly launched phase 2 study, which is exploring the agent for the treatment of adult women with recurrent or persistent uterine serous carcinoma.

August 04, 2021

Stephanie Lee, MD, MPH, discusses the study of ruxolitinib plus best available therapy as a second-line treatment for patients with chronic graft-versus-host disease.

August 04, 2021

During a Targeted Oncology Case-Based Roundtable event, Andrew Kuykendall, MD, discussed the case of 68-year-old patients with myelofibrosis.

August 04, 2021

The combination of plinabulin with docetaxel showed improvement in overall survival compared with docetaxel alone as treatment of patients with second- and third-line non –small cell lung cancer with EGFR wild type, meeting the primary end point of the phase 3 DUBLIN-3 clinical trial.

August 04, 2021

In an interview with Targeted Oncology™, Kamran A. Ahmed, MD, discussed the novel treatment strategy of combining radiotherapy with intrathecal trastuzumab/pertuzumab as well as and the rationale behind the combination.

August 04, 2021

Bijal Shah, MD, MS, discusses the results of treatment with the chimeric antigen receptor T-cell therapy brexucabtagne autoleucel in the ZUMA-3 trial in patients with acute lymphoblastic leukemia.

August 03, 2021

Justine Kahn, MD, MS, discusses the Children’s Oncology Group study that identified a survival disparity among patients with de novo Hodgkin lymphoma of different races and economic statuses.

August 03, 2021

In an interview with Targeted Oncology™, Rhonda L. Bitting, MD, discussed the efficacy results and key takeaways of a study investigating low-dose paclitaxel plus pembrolizumab in patients with platinum-refractory UC. 

August 03, 2021

In a Targeted Oncology Case-Based Roundtable event Edward S. Kim, MD, MBA, discussed new regimens for the treatment of non-small cell lung cancer.

August 03, 2021

Bristol Myers Squibb has decided to withdraw the approval for romidepsin, a histone deacetylase inhibitor, for the treatment of adults with peripheral T-cell lymphoma who received at least 1 prior therapy after a confirmatory phase 3 study missed its primary end point.